Trim 30-50% into $207-212 rally; hard re-evaluation at Q3 earnings with $179 as full exit trigger
Underweight is the appropriate rating given the convergence of fundamental uncertainty ($9.30 forward EPS requires 65% recovery from $5.61 TTM with no confirmed bridge), bearish technical confirmation (200 SMA rolling over, price lost 10 EMA at $202.59, MACD histogram compressing in distribution), and asymmetric risk/reward into a binary Q3 catalyst. The 30-50% trim range is calibrated to preserve defensive ballast exposure (Diagnostics ~50% of revenue, $5.3B FCF, 2.0-2.8x net debt/EBITDA, $3B annual buyback) while protecting against downside if forward EPS gets revised toward $8.00-8.50. The $200 SMA serves as core position invalidation, with $179 as the structural floor triggering full exit.
| Position | Action |
|---|---|
| Price rallies to $207-212 zone | Trim 30-50% of target weight (sell into rally, don't wait for perfect $209 print) |
| Price declines to $197-200 zone | Do NOT add—this zone becomes a breakdown trigger, not a buying opportunity |
| Close below $179 on heavy volume | Full exit consideration—invalidates entire quality compounder thesis |
| Re-entry trigger | Confirmed close above $210 with MACD histogram turning positive and volume >3M |
The setup at $202 is an asymmetric entry into a high-quality compounding machine in healthcare, trading at trough earnings with a recovery thesis priced at just 21.8x forward earnings.
| Indicator | Value | Signal |
|---|---|---|
| 200-day SMA | $202.45 | neutral |
| 50-day SMA | $192.88 | bullish |
| 10-day EMA | $202.59 | bearish |
| RSI | 55.32 | neutral |
| MACD Line | 3.56 | neutral |
| MACD Signal | 3.21 | neutral |
| MACD Histogram | +0.35 | bearish |
| Bollinger Middle (20 SMA) | $197.60 | bullish |
| Bollinger Upper | $213.56 | bearish |
| Bollinger Lower | $181.64 | bullish |
| VWMA |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $210 with MACD histogram rebuilding and volume >3M
Then: Re-evaluate for potential re-entry on bullish catalyst confirmation
↩ rebuts: “Bear's unfavorable TMO comparison showing DHR didn't raise guidance”
EV: $230+ on Q3 earnings confirmation · concedes: Not a momentum trade — won't rip 20% in 60 days on catalysts alone; Bioprocessing recovery will take time; Technical setup needs confirmation above $209.37
DHR's "asymmetric setup" is a value trap in slow motion—the stock looks cheap on forward earnings until those earnings get revised down, at which point it looks expensive on the new lower estimates.
· concedes: The bull is a sophisticated advocate presenting his case well; Capital return story ($3.1B buybacks) is real, though insufficient as primary thesis; Diagnostics (~50% revenue) provides some ballast, though not enough to drive 65% EPS recovery alone; The 50 SMA hasn't rolled over yet (lagging confirmation)
→ vs conservative: Selling into the $209-215 resistance zone creates 2.5% give-up for a potential 4-6% downside scenario the technicals actually argue against; adding at $197-198 is the correct move, not a risk to avoid
→ vs neutral: Waiting until Q3 earnings in late October to act is paralysis, not patience—missing a technical pivot where multiple indicators align because you want confirmation is leaving money on the table
→ vs conservative: Bioprocessing weakness is cyclical noise, not structural decay; the bearish thesis ignores that Diagnostics likely remained steady at ~50% of revenue, and one soft quarter doesn't define a franchise of Danaher's scale
→ vs conservative: The $9.30 forward EPS criticism is anchoring bias—comparable-basis earnings trajectory is obscured by the Veralto spin-off inflating 2021 baseline
| $200.07 |
| bullish |
| ATR | $6.40 | neutral |
| 08-10 High | $209.37 | neutral |
| 08-14 Low | $201.12 | neutral |
| 05-15 Low | $165.92 | neutral |
| 07-21 Low | $179.01 | neutral |
Support: 197.6 · 192.88 · 181.64 · 179.01 | Resistance: 202.59 · 209.37 · 213.56
DHR closed at $202.45 on 2026-08-14, precisely testing its 200-day SMA at the same level—a critical make-or-break inflection point after recovering from a mid-summer crash low of ~$165. The medium-term trend is improving as the 50 SMA rises to $192.88 and price holds above it, but short-term momentum has cooled with RSI declining from 64.59 to 55.32 and MACD histogram compressing to +0.35 from a recent peak of 3.90, suggesting the bullish momentum is decelerating. Volatility remains elevated at ATR $6.40 (~3.2% daily range), and the recommendation is HOLD/wait-and-see, with bulls needing to defend $200 and a confirmed close below $197.60 (Bollinger mid) invalidating the recovery thesis.
Market Cap
$142.32 B
TTM Revenue
$25.11 B
TTM Net Income
$3.99 B
TTM EPS
$5.61
Forward EPS
$9.30
Beta
0.80
Dividend Yield
0.78%
P/E (TTM)
36.09x
Forward P/E
21.77x
PEG Ratio
1.34
P/B
2.71x
52-Week Range
$160.93 – $242.80
50-Day MA
$192.51
200-Day MA
$203.20
Revenue (2021)
$26,643 M
Revenue (2022)
$23,890 M
Revenue (2023)
$23,890 M
Revenue (2024)
$23,875 M
Revenue (2025)
$24,568 M
Gross Profit (2021)
$16,188 M
Gross Profit (2022)
$14,034 M
Gross Profit (2023)
$14,206 M
Gross Profit (2024)
$14,523 M
Operating Income (2021)
$7,536 M
Operating Income (2022)
$5,202 M
Operating Income (2023)
$4,863 M
Operating Income (2024)
$4,690 M
EBITDA (2021)
$9,752 M
EBITDA (2022)
$9,482 M
EBITDA (2023)
$7,496 M
EBITDA (2024)
$7,276 M
EBITDA (2025)
$6,945 M
Net Income (2021)
$7,209 M
Net Income (2022)
$4,764 M
Net Income (2023)
$3,899 M
Net Income (2024)
$3,614 M
Net Income (2025)
$3,610 M
Diluted EPS (2021)
$9.80
Diluted EPS (2022)
$6.44
Diluted EPS (2023)
$5.33
Diluted EPS (2024)
$5.07
Diluted EPS (2025)
$5.05
Gross Margin (2021)
60.8%
Gross Margin (2022)
58.7%
Gross Margin (2023)
59.5%
Gross Margin (2024)
59.1%
Gross Margin (2025)
~59%
Operating Margin (2021)
28.3%
Operating Margin (2022)
21.8%
Operating Margin (2023)
20.4%
Operating Margin (2024)
19.7%
Operating Margin (2025)
19.1%
TTM Operating Margin
19.8%
TTM Net Margin
15.9%
R&D Spend (2021)
$1,528 M
R&D Spend (2022)
$1,503 M
R&D Spend (2023)
$1,584 M
R&D Spend (2024)
$1,598 M
ROE
7.6%
ROA
3.9%
EBITDA Margin
~32%
Revenue 5Y CAGR
~(-2%)
Revenue 2024 to 2025 Growth
+2.9%
Forward EPS Growth
+65%
Total Assets (2021)
$84,350 M
Total Assets (2022)
$84,488 M
Total Assets (2023)
$77,542 M
Total Assets (2025)
$83,464 M
Goodwill (2021)
$37,276 M
Goodwill (2022)
$41,608 M
Goodwill (2023)
$40,497 M
Goodwill (2025)
$43,151 M
Tangible Book Value
$-8.4B
Total Equity (2021)
$50,082 M
Total Equity (2022)
$53,486 M
Total Equity (2023)
$49,543 M
Total Equity (2025)
$52,534 M
Total Debt (2021)
$20,616 M
Total Debt (2022)
$19,536 M
Total Debt (2023)
$17,146 M
Total Debt (2025)
$19,696 M
Cash and Equivalents (2021)
$5,995 M
Cash and Equivalents (2022)
$5,864 M
Cash and Equivalents (2023)
$2,078 M
Cash and Equivalents (2025)
$4,615 M
Net Debt (2021)
$13,682 M
Net Debt (2022)
$12,538 M
Net Debt (2023)
$13,927 M
Net Debt (2025)
$13,803 M
Net Debt to EBITDA
~2.0x
Working Capital (2021)
$7,494 M
Working Capital (2022)
$5,663 M
Working Capital (2023)
$2,699 M
Working Capital (2025)
$5,949 M
Current Ratio (2022)
1.68
Current Ratio (2023)
1.40
Current Ratio (2025)
1.87
TTM Current Ratio
1.65
Operating Cash Flow (2021)
$8,519 M
Operating Cash Flow (2022)
$7,164 M
Operating Cash Flow (2023)
$6,688 M
Operating Cash Flow (2025)
$6,416 M
Capital Expenditure (2021)
$1,118 M
Capital Expenditure (2022)
$1,383 M
Capital Expenditure (2023)
$1,392 M
Capital Expenditure (2025)
$1,156 M
Free Cash Flow (2021)
$7,401 M
Free Cash Flow (2022)
$5,781 M
Free Cash Flow (2023)
$5,296 M
Free Cash Flow (2025)
$5,260 M
FCF Margin (2021)
27.8%
FCF Margin (2022)
24.2%
FCF Margin (2023)
22.2%
FCF Margin (2025)
21.4%
Dividends Paid (2021)
$818 M
Dividends Paid (2022)
$1,248 M
Dividends Paid (2023)
$768 M
Dividends Paid (2025)
$878 M
Buybacks (2022)
$0
Buybacks (2023)
$5,979 M
Buybacks (2024)
$6,000 M
Buybacks (2025)
$3,088 M
Acquisitions (2021)
$582 M
Acquisitions (2022)
$5,610 M
Acquisitions (2023)
$558 M
Acquisitions (2025)
$0
Net Debt Issued Repaid (2021)
($1,688) M
Net Debt Issued Repaid (2022)
($1,626) M
Net Debt Issued Repaid (2023)
($1,669) M
Net Debt Issued Repaid (2025)
$1,045 M
Share Count Reduction
~3%
Abcam Acquisition Cost
~$5.7B
Cytiva Acquisition
$21B
5-Year Cumulative Shareholder Returns
~$12B+
Strengths
Concerns
Danaher Corporation is a high-quality healthcare compounder currently in an earnings trough, with operating margins compressed to 19.1% from historical norms of 28%+ due to post-COVID destocking, elevated R&D investment, and Abcam integration costs. The stock offers an attractive setup with TTM P/E of 36.1x versus Forward P/E of 21.8x, implying analyst consensus expects near-doubling of EPS as bioprocessing demand normalizes and synergies materialize; however, this recovery requires patience and conviction in management's ability to restore operating leverage. The balance sheet remains investment-grade with $5.3B in annual FCF, enabling $3.1B in 2025 buybacks, though the $43B goodwill position reflects significant M&A reliance and the ~$5.7B Abcam acquisition closed in December 2024 adds integration complexity. The stock is best held or accumulated on weakness by long-term investors — it requires earnings proof to re-rate higher and is not currently a momentum trade.
Macro: Mild restrictive monetary policy with 85% probability of no Fed rate cuts in 2026 (Polymarket, steady past week); soft-landing backdrop with US recession odds at only 8% (down 0.5pp weekly) and UK at 10% (down 5.5pp weekly); disinflation dominant with 18% probability of >4.5% inflation in 2026 (down 3.0pp weekly) and 8% for >5% (down 5.0pp weekly); weak US retail sales confirmed per multiple headlines. Mixed-to-supportive environment for high-quality defensive healthcare compounders but not constructive for multiple expansion.